Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 32 Page 33 Page 34 Page 35 Page 36 Page 37 Page 38 Page 39 Page 40 Page 41 Page 42 Page 43 Page 44ng Trends Data Analysis Biosimilars ernative Medicine Individualized Care Data Analysis Data Analysis 23 MONDAY, SEPTEMBER 18, 2017 Data Analysis MONDAY, SEPTEMBER 18, 2017 Data Analysis l Data Analysis l Data AnalysisSymposium 6 Data AnalysisSymposium 6 Data Analysis l 8:00 – 9:30 am Therapeutic Options for Obesity Treatment in Children, Adolescents & Young Adults APPLICATION TRACK Offers both CME and CPE Credit UAN #0238-0000-17-012-L05-P ACPE – 1.5 CONTACT HOURS/APPLICATION-BASED CO-CHAIRS: Catherine MT Sherwin, PhD, MS, Chief, Div of Clinical Pharmacology, Univ of Utah Janelle D. Vaughns, MD, Assistant Professor of Anesthesiology & Pediatrics, Children’s National Health System TARGET AUDIENCE: The primary audience is clinical and research faculty from schools and colleges of medicine, pharmacy and nursing. It would also include pharmacologists, pharmacists, clinicians or graduate/postgraduate trainees wishing to better understand the implications of consensus guidelines on prescribing practices for obese patients. GOALS AND OBJECTIVES: Following completion of this activity, the learner will be able to: 1. Update participants on the therapeutic options for obesity treatment in children, adolescents and young adults; 2. Review the evidence-based dosing guidelines for commonly-used drugs in these special patient groups and describe what effective treatment options are available; 3. Explain concerns related to the scientific and regulatory challenges underlying the prescribing of drugs to obese patients; 4. Provide an overview on the clinical application of population pharmacokinetic/pharmacodynamic modeling and the use of mechanism-based analysis to individualized dosing schemes in morbidly obese children, adolescents and young adults. 8:00 – 8:20 am Role of Pharmacologic Dosing Strategies in General Anesthesia During the Perioperative Period in Obese Children & Adolescents Janelle D. Vaughns, MD, Assistant Professor of Anesthesiology & Pediatrics, Children’s National Health System 8:20 – 8:40 am How Do We Get Effective Therapeutic Options for Families With Children Dealing With Obesity? Mark Templeman, MD, Pediatrician, Intermountain Hillcrest Pediatrics 8:40 – 9:00 am Implications to Regulations & Labeling of Drugs for Therapeutics Used in Children, Adolescents & Young Adults Dionna J. Green, MD, Medical Officer & Policy Lead, Office of Clinical Pharmacology, Ctr for Drug Evaluation & Research, US Food & Drug Administration 9:00 – 9:20 am The Influence of Morbid Obesity on the Pharmacokinetics & Pharmacodynamics of Drugs: Implications for Individualized Dosing Catherijne Knibbe, PhD, PharmD, Professor, Individualized Drug Treatment, St Antonius Hosp, Dept of Clinical Pharmacy 9:20 – 9:30 am Panel Discussion This Symposium is supported in part by the British Journal of Clinical Pharmacology. Symposia